prikaz prve stranice dokumenta Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential
  Download
PDF 154.92 KB
Scientific paper - Original scientific paper
Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential
Clinical Oral Investigations, 22 (2018), 2; 1071-1082. https://doi.org/10.1007/s00784-017-2190-3
Lončar-Brzak, Božana; Klobučar, Marko; Veliki-Dalić, Irena; Sabol, Ivan; Kraljević Pavelić, Sandra; Krušlin, Božo; Mravak-Stipetić, Marinka

Cite this document

Lončar Brzak, B., Klobučar, M., Veliki Dalić, I., Sabol, I., Kraljević Pavelić, S., Krušlin, B. & Mravak Stipetić, M. (2018). Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential. Clinical Oral Investigations, 22. (2), 1071-1082. doi: 10.1007/s00784-017-2190-3

Lončar Brzak, Božana, et al. "Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential." Clinical Oral Investigations, vol. 22, no. 2, 2018, pp. 1071-1082. https://doi.org/10.1007/s00784-017-2190-3

Lončar Brzak, Božana, Marko Klobučar, Irena Veliki Dalić, Ivan Sabol, Sandra Kraljević Pavelić, Božo Krušlin and Marinka Mravak Stipetić. "Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential." Clinical Oral Investigations 22, no. 2 (2018): 1071-1082. https://doi.org/10.1007/s00784-017-2190-3

Lončar Brzak, B., et al. (2018) 'Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential', Clinical Oral Investigations, 22(2), pp. 1071-1082. doi: 10.1007/s00784-017-2190-3

Lončar Brzak B, Klobučar M, Veliki Dalić I, Sabol I, Kraljević Pavelić S, Krušlin B, and sur.. Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential. Clinical Oral Investigations [Internet]. 2018 March [cited 2024 April 28];22(2):1071-1082. doi: 10.1007/s00784-017-2190-3

B. Lončar Brzak, et al., "Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential", Clinical Oral Investigations, vol. 22, no. 2, pp. 1071-1082, March 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:615495. [Accessed: 28 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential
AuthorBožana Lončar-Brzak
AuthorMarko Klobučar
AuthorIrena Veliki-Dalić
AuthorIvan Sabol
AuthorSandra Kraljević Pavelić
AuthorBožo Krušlin
AuthorMarinka Mravak-Stipetić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
OBJECTIVES: The aim of this study was to examine molecular alterations on the protein level in lesions of oral lichen planus (OLP), oral squamous cell carcinoma (OSCC) and healthy mucosa. ----- MATERIALS AND METHODS: Global protein profiling methods based on liquid chromatography coupled to mass spectrometry (LC-MS) were used, with a special emphasis on evaluation of deregulated extracellular matrix molecules expression, as well as on analyses of IG2F and IGFR2 expression in healthy mucosa, OLP and OSCC tissues by comparative semi-quantitative immunohistochemistry. ----- RESULTS: Mass spectrometry-based proteomics profiling of healthy mucosa, OLP and OSCC tissues (and accompanied histologically unaltered tissues, respectively) identified 55 extracellular matrix proteins. Twenty among identified proteins were common to all groups of samples. Expression of small leucine-rich extracellular matrix proteoglycans lumican and biglycan was found both in OSCC and OLP and they were validated by Western blot analysis as putative biomarkers. A significant increase (p < 0.05) of biglycan expression in OLP-AT group was determined in comparison with OLP-T group, while lumican showed significant up-regulation (p < 0.05) in OLP-T and OSCC-T groups vs. adjacent and control tissue groups. Biglycan expression was only determined in OSCC-AT group. Immunohistochemical analysis of IGF2 and IG2FR expression revealed no significant difference among groups of samples. ----- CONCLUSION/CLINICAL RELEVANCE: Biglycan and lumican were identified as important pathogenesis biomarkers of OLP that point to its malignant potential.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleClinical Oral Investigations
Numberingvol. 22, no. 2, pp. 1071-1082
p-ISSN1432-6981
DOIhttps://doi.org/10.1007/s00784-017-2190-3
URN:NBNurn:nbn:hr:105:615495
Publication2018-03
Document URLhttps://doi.org/10.1007/s00784-017-2190-3
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:24:04